EGFR and non-small cell lung carcinoma: Additionally, at its current cost, osimertinib is not a cost‐effective first‐line therapy for EGFR‐mutated NSCLC according to the World Health Organization cost‐effectiveness threshold criteria,21 so afatinib may be a good alternative for first‐line treatment.